JMP Securities analyst Reni Benjamin downgrades LAVA Therapeutics (NASDAQ:LVTX) from Market Outperform to Market Perform and maintains the price target from $6 to $6.
JMP Securities Downgrades LAVA Therapeutics to Market Perform, Maintains Price Target to $6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.